Molecular Mechanisms of PBDEs in Breast Cancer Cells and Xenografts

Experimental data assesses the biological activities of three PBDE congeners (BDE-47, -100, -153) in breast cancer. The study uses receptor binding assays, RNA-sequencing in MCF-7aroERE cells, and in vivo patient-derived xenograft models. It was authored by Noriko Kanaya and last updated in 2019.

Use Cases

• Analyze PBDE congener-specific effects on nuclear receptor signaling pathways like ERα, ERRα, and AhR.
• Investigate gene expression changes, including ER-regulated and cell cycle genes, from RNA-sequencing data.
• Evaluate in vivo estrogenic activity of a PBDE mixture using PDX model endpoints like apoptosis and Ki-67 expression.
• Compare the agonist/antagonist profiles of BDE-47, BDE-100, and BDE-153 on estrogen receptor activity.

Strengths

• Data is derived from three complementary experimental strategies: biochemical assays, transcriptomics, and in vivo models.
• Focuses on three specific, environmentally relevant PBDE congeners frequently detected in human serum.
• Associated with a peer-reviewed study published in 2019, providing scientific context.

Limitations

• The specific data structure, row count, column names, and file formats are not provided in the input.
• The dataset's temporal coverage and sample size for in vitro and in vivo experiments are not specified.
• Data is from 2019 and may not reflect the most recent research findings in the field.

Provenance

Source

Dryad digital repository.

Collection Method

Generated from laboratory experiments including receptor binding/activity assays, RNA-sequencing, and patient-derived xenograft models.

Freshness

Last updated 2019-06-26.